Osteosarcoma is a primary malignant bone tumor that has a high potential to metastasize to lungs. Little is known about the mechanisms underlying the dissemination of OS cancer cells to lungs. We performed whole exome sequencing of 13 OS primary tumors, with matched lung metastases and normal tissues. Phylogenetic analyses revealed that lung metastatic tumors often harbor clones that are nonexistent or rare in the matched primary OS tumors. Spatially and temporally separated lung metastases were from parallel seeding events with a polyphyletic pattern. Loss of TP53 or RB1 is among the early events during OS tumorigenesis, while loss of PTEN is involved at the later stages associated with lung metastases. Finally, KEAP1 was identified as a novel biomarker for increased metastatic risk. Patients whose primary tumors harbored KEAP1 amplification have significantly poorer lung-metastasis free survival. This finding was validated in two independent datasets. Further, in vitro experiments exhibited that KEAP1 depletion suppressed the invasion of OS cells. Our findings uncover the patterns of clonal evolution during OS progression and highlight KEAP1 as a novel candidate associated with the risk of lung metastasis in OS patients.
Introduction
Osteosarcoma (OS) is a prevalent primary malignant bone tumor that mostly occurs in children and adolescents. 1 OS has a high potential to metastasize, and lung metastasis is the leading cause of death. The etiology of OS remains poorly understood due to the rarity of this highly aggressive cancer and the difficulty of obtaining an adequate sample with high tumor content for further analyses. 2 Few clinically actionable mutations have been reported and no further improvements regarding survival have been made in the last decades.
Therefore, prognostic biomarkers for the development of lung metastases in OS patients may improve personalized cancer care. Previous genomic studies mainly focused on primary OS tumors. [4] [5] [6] [7] Although these studies detailed the patterns of somatic alterations in primary tumors, a comparative study of the samples from primary and matched lung metastases has not been performed to our knowledge. The genomic heterogeneity between primary OS tumors and lung metastases as well as the intermetastatic heterogeneity still remains unclear. Further, how the subclonal diversity of tumors changes during metastasis is poorly understood in OS during progression. Such information would be useful in understanding the molecular mechanisms of OS progression and to determine proper treatment or prognosis strategies.
To investigate the genomic alterations and the evolutionary process associated with OS progression and lung metastasis, we performed deep whole exome sequencing (WES) of matched, OS primary tumors, lung metastases and normal control tissues in 13 patients. We sought to: (i) compare genomic alterations between paired primary and metastatic tumors; (ii) define the subclone structures and their evolutionary phylogeny in primary and metastatic tumors in each patient, and (iii) identify and validate candidate genes associated with lung metastases and clinical outcomes.
Material and Methods

Sample information
The dataset comprised 13 primary OS tumor samples (postchemotherapy), paired with normal bone-marrow control samples and lung metastasis samples. One patient had three recurrent lung metastases. All samples were from postchemotherapy biopsies of OS patients. Clinical characteristics and sample IDs of all samples from 13 OS patients are presented in Table S1 . For example, the sample ID of the normal control sample from patient P7 is OS7-N, and the ID of its corresponding primary and metastatic tumor sample is OS7 and OS7-L, respectively. Written consents were obtained from all the patients and ethical approval (2014-98) for our study was obtained from the ethics committee of the First Affiliated Hospital of Sun Yat-Sen University.
Whole exome sequencing
Genomic DNA from formalin-fixed paraffin-embedded (FFPE) samples was extracted using QIAamp DNA FFPE Tissue Kit (Qiagen), and fragmented by M220 Focusedultrasonicator (Covaris) into 250 bp. Whole genome library was prepared using KAPA Hyper Prep Kit (KAPA Biosystems). Exome capture was performed using the Illumina Rapid Capture Extended Exome Kit (Illumina Inc.). Enriched libraries were sequenced using the Illumina HiSeq 2500 platform as paired 125-bp reads, to reach the mean coverage of 803 for the normal control and 2503 for the tumor samples (Supporting Information Table S2 ). Raw sequencing data has been deposited to NCBI SRA database (PRJNA400619). One European OS patient (treatment naive) with paired primary and metastatic samples from a public available WES dataset (ENA database, PRJEB11430) was also included for the analysis.
Sequencing data analyses
Paired-end sequencing data from the exome capture libraries were aligned to the reference human genome (build hg19) with the Burrows-Wheeler Aligner (bwa-mem). 8 Alignment results (BAM files) were further processed for de-duplication, base quality recalibration and indel realignment using the Picard suite 9 (http://picard.sourceforge.net/) and the Genome Analysis Toolkit (GATK). 10 MuTect 11 with default parameters was applied to paired normal and tumor BAM files for identification of somatic single nucleotide variants (SNVs). For somatic SNV calls, we applied four exclusion filters: (i) <8 alternate reads in tumor samples; (ii) <10% variant allele frequency (VAF); (iii) <20 reads in total in the tumor and control samples; (iv) presence of the variant in the 1000 Genomes project at frequency >1%. All the somatic SNVs were then annotated by Oncotator. 12 Numbers of non-silent SNVs and overlap of these SNVs between the primary and the corresponding metastatic tumors for each patient were provided in Supporting Information Figure S1 . Gene-level copy ratios were calculated by CNVKit. 13 Using CNVKit algorithm, relative copy-ratios for each exon were calculated by correcting for imbalanced library size, GC bias, sequence repeats and target density.
Phylogenetic analysis
Canopy 14 was used for inferring cancer cell subpopulations, the mutation profile of each subpopulation and its contributing proportion to the sample and the underlying phylogeny. Allele-specific arm-level CNAs were identified by FACETS. 15 What's new?
The spread of cancer cells to the lungs in osteosarcoma is difficult to control and can fuel further progression of the disease. Little is known, however, about the mechanisms behind lung metastasis in osteosarcoma. Here, comprehensive whole exome sequencing comparing genetic alterations between primary and metastatic osteosarcomas shows that metastatic tumors harbor clones that are unique from those of primary tumors. Specific genetic events were identified in association with tumor progression. In particular, KEAP1 amplification was associated with significantly worse lung metastasis-free survival, making it a potentially valuable biomarker for increased metastatic risk in osteosarcoma patients.
Non-silent SNVs and arm-level CNAs were used as suggested by Canopy. The number of subclones was set to 3, 4, 5, 6, 7, and 8 for testing. We used Bayesian Information Criterion (BIC) as a model selection criterion to determine the optimal number of subclones. Canopy further performed a posterior evaluation of all sampled trees by Markov Chain Monte Carlo method and the tree with the highest posterior likelihood was chosen. The output of Canopy is the cell fraction of each clone in each tumor sample and the phylogenetic relationship among these clones.
To build the phylogenetic relationship among the primary tumor and multiple metastatic tumors in patient P13, neighbour joining (NJ) tree was built based on the pairwise distance matrices (1-q, spearman correlation coefficient) for CNA. We also build NJ tree for SNVs using the distance matrices based on the presence of somatic SNVs in each sample. NJ trees were built with the use of the "analyses of phylogenetics and evolution" (APE) package 16 implemented in R version 3.3.0.
Survival analyses
We analyzed PTEN and KEAP1 gene expression level and the corresponding patients' survival data (GEO database: GSE21257) 17 on pre-treatment biopsies of 53 OS patients who did (n 5 34) or did not (n 5 19) develop metastases within 5 years. Patients were divided into high and low expression groups based on the median expression levels of candidate genes (PTEN, KEAP1). Kaplan-Meier survival curves were generated with the use of "survival" and "survminer" R packages to compare lung-metastasis free survival distributions between the high and the low expression groups. Statistical significance was assessed using the LogRank test.
Lentiviral transduction
U2OS/MTX300 cells were gifts from Dr. M. Serra (Istituti Ortopedici Rizzoli, Bologna, Italy) and were grown in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) at 378C with 5% CO2. The purity and authenticity of cell line used in these studies were independently confirmed through short tandem repeat (STR) profiling performed by the Genewiz, Inc (Suzhou, China). For stable cell line construction, plasmids containing short hairpin RNA (sh-KEAP1) against human KEAP1 gene and negative control (random hairpin shRNA) were obtained from GeneCopoeia, and packaged into the recombinant lentiviruses by Lenti-PacTM HIV Expression Packaging Kit (GeneCopoeia). After three rounds of infection, stable transfected cells with strong GFP expression were selected by fluorescenceactivated cell sorting (FACS). Western blotting with KEAP1 antibody (Abcam) was used to confirm the knockdown efficiencies, and the most two effectively stable knockdown cell lines were chosen for the further experiments. GAPDH (Abcam) antibody was used as loading control. Antibody for detection of MMP9 protein level was purchased from Abcam.
Transwell assay
Transwell assay was performed using 24-well transwells (8.0-lm pore size) with Matrigel coating (BD Biosciences). Briefly, 2.0 3 10 4 U2OS/MTX300 cells were seeded in the upper chamber of a transwell containing 200 ll of DMEM without FBS, and the well of the lower chamber was filled with 500 ll of DMEM with 10% FBS. After incubation for 24 hr, the cells remaining in the upper chamber were removed via wiping with a cotton swab, and the cells that had migrated to the lower side of the filter were fixed with 4% paraformaldehyde followed by crystal violet staining and microscopic examination. The numbers of migrated or invading cells were counted in five random visual fields, and all assays were performed in three independent experiments. In each experiment, the cell line was set up as triplicate, and the average of cell counts from each well was calculated. The data represented was the mean 6 SD of the average cell counts from three independent experiments, and the statistic comparison between the negative control and sh.KEAP1 #1 or #2 infected cell lines was analyzed using t test.
Western blot
Western blot analysis was performed using standard procedures. Briefly, 60 lg of protein extracted from indicated cells were separated by 12% SDS-PAGE and transferred to PVDF membranes. The membranes were blocked in 5% nonfat dry milk in 1X TBST, and then incubated with specific primary antibodies as follow: KEAP1 (CST, #4678, 1:1000), MMP9 (Bioworld, BS1241, 1:500), NRF2 (Abcam, ab137550), and GAPDH (Abcam, ab128915, 1:10000), respectively. Subsequently, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 1 hr at room temperature. The protein bands were visualized with the enhanced chemiluminescence (ECL) detection system using a GE ImageQuant LAS4000 mini. Three independent western blot experiments were performed for confirmation, with one representative blot showing in the figure.
Results
Landscape of somatic mutations in primary and metastatic OS tumors
We performed deep WES of the matched, OS primary tumors, lung metastases and normal bone marrow tissues from 13 OS patients. The detailed clinical characteristics and sample identifications (ID) of all samples from 13 OS patients are presented in Supporting Information Table S1 . For example, the sample ID of the normal control sample from patient P7 is labeled as OS7-N, its corresponding primary tumor sample is OS7, and its corresponding lung metastasis is OS7-L. Somatic SNVs were identified ranging from 0 to 263 (median: 46) per sample (Supporting Information Table S3 ), among which a median of 10 somatic SNVs (range 1-45) were non-silent (missense and nonsense) mutations within the protein-coding regions (Supporting Information Fig. S1 ). The tumor mutation burden (TMB) was estimated as 0.3 nonsilent mutations per megabase (MB), assuming 30 MB 18 of protein coding region in the human genome. This is consistent with the previous studies showing low TMB around 0.1-0.5 mutations per MB in pediatric OS tumors. 19 Only five genes (TP53, LRP1B, MROH9, TBC1D4, and NBPF1) were mutated in at least two patients, suggesting highly genetic heterogeneity among patients.
Copy number alterations in primary OS tumors and lung metastases
Although OS has extremely low TMB, it is a malignant tumors with abundant structural aberrations and CNAs. 4, 7, 20 Recent studies have detailed the genome-wide CNAs of the primary OS tumors, 4 but the comparison between metastatic and primary tumors has not been characterized. To explore the relationships between primary and metastatic tumor samples, unsupervised hierarchical clustering was performed based on their genome-wide CNAs patterns. Since tumor content (or purity) has a significant impact on clustering analysis, we excluded patients having tumor samples with both low-purity (<30% estimated by FACETS 15 ) and nonedetectable somatic SNVs. As a result, six patients (P7, P8, P10, P13, P15 and P16) from our study and one European patient (P253) from the public available dataset were used for clustering analysis. Our results showed that matched primary and metastatic tumors from the same patient always clustered together with the similar pattern of CNAs (Fig. 1a and 1a) . These results indicate that tumors from the same patient are more genetically similar to each other than the tumors from other patients, consistent with the clonal expansion model 21 and patient specific evolutionary histories. In patient P13 with three different lung metastatic tumors, one (OS13-L1) of the metastases was more closely related to the primary tumor than to the other metastases (OS13-L2 and OS13-L3; Fig.1a) , suggesting a polyphyletic relationship among three metastases.
Several arm-level CNAs occurred highly frequent. For example, loss of 13q (harboring RB1, BRAC2) was identified in both primary and metastatic tumors from 7 patients. Although we observed overall CNA similarity between the primary and metastatic tumors, as suggested by hierarchical clustering, few metastatic (or primary) specific CNAs were also found in individual patient. In patient P10, amplification of chromosome 2q, 8q (harboring MYC) and deletion of 3p, 6q, 13 (harboring RB1 and BRAC2) were observed in both primary and metastatic tumors. However, chromosome 19p amplification and 10q deletion (harboring PTEN) were found specific in metastatic tumor in patient P10. In patient P16, a focal amplification at 11q13.3 harboring CCND1 was detected only in metastatic tumor.
High level of KEAP1 predicts increased metastatic risk
We detected that the degree of amplification of a focal region (19p13.2) in metastatic tumors increased when compared to the matched primary tumors in three patients (P10, P15, and P253). One interesting gene within this amplified region is KEAP1, which has been spotlighted in several previous studies. For example, a previous study demonstrated that KEAP1-knockdown mice have increased resistance against the cancer cell metastasis to the lung. 22 Cell invasion was also found to be reduced in the KEAP1-knockdown breast carcinoma cells. 23 To further test whether the amplification of KEAP1 in primary tumor alone can predict higher probability of developing lung metastasis, we analyzed the copy number of KEAP1 in all primary tumors and identified six patients (P4, P10, P12, P13, P15, P253) harbored KEAP1 amplification (log2 depth ratio >50.2, CNVKit) (Supporting Information  Table S4 ). Indeed, patients with amplified KEAP1 in their primary tumors exhibited significantly (p 5 0.01, log-rank test) poorer lung metastasis-free survival (Fig. 2a) . Although several other genes around KEAP1 harbored copy number gain in different primary tumor samples, KEAP1 is the only gene whose copy number status showing significant association with lung metastasis-free survival (Supporting Information Table S5 ). We further identified 31% (9/29) of OS patients (without treatment) in a publicly available dataset (GSE33153) exhibited KEAP1 copy number amplification, with elevated KEAP1 expression level, and no samples harbored KEAP1 deletion (Supporting Information Fig. S2) . Thus, the amplification of KEAP1 is relatively common in OS and the expression of KEAP1 is positively correlated with its copy number.
To further validate the association between higher level of KEAP1 and lung metastasis in larger cohorts, we compared the genome-wide gene expression profiling on pre-chemotherapy biopsies samples (GEO database: GSE21257) from patients who had already developed lung metastasis at diagnosis (n 5 14, lung-meta group) and metastasis-free over 5 years after diagnosis (n 5 19, meta-free group), and KEAP1 exhibited significantly (p < 0.001, t test) higher expression in lung-met group (Fig. 2b) . We further divided all (n 5 53) patients into the high or the low expression groups based on the median expression level of KEAP1 as cutoff. Patients with higher KEAP1 expression level exhibited significantly (p 5 0.002, log-rank test) poorer lung metastasis-free survival rate (Fig. 2c) . However, patients with higher KEAP1 expression only exhibited a non-significant trend (p 5 0.09, log-rank test) toward poorer overall survival (Supporting Information Fig. S3 ). We next validated our finding using another large publicly available dataset of 102 OS patients whose KEAP1 status was measured by immunohistochemical staining (protein level), 24 and they did not receive radiotherapy or chemotherapy before surgery. Consistently, patients with positive staining of KEAP1 had significantly (p 5 0.003, fisher exact test) higher percentage of metastases at diagnosis compared to the negative staining group (Fig. 2d) . In summary, from three independent datasets at DNA, RNA and protein levels, we consistently observed that high level of KEAP1 is highly enriched in OS patients with lung metastasis at diagnosis. Taken together, these results suggest that increased level of KEAP1 is highly associated with increased metastatic risk in OS.
To further explore the function of KEAP1 in OS progression and lung metastasis, we investigated the roles of KEAP1 on OS cells invasion. KEAP1 was silenced by two independent shRNA (sh.KEAP1) in U2OS/MTX OS cells (Fig. 2e) . Compared to negative control, KEAP1 knockdown significantly (p < 0.001) blocked OS cells from crossing the barrier in the chamber of the transwell assay ( Fig. 2f and Supporting Information Fig. S4) . Interestingly, MMP9, a metalloproteinase involved in breakdown of extracellular matrix, 25 which may facilitate OS cell metastasis, was downregulated followed by KEAP1 suppression (Fig. 2e) . NRF2, a direct target gene of KEAP1, was upregulated followed by KEAP1 suppression (Fig. 2e) . These results indicate that KEAP1 depletion can effectively inhibit the invasion of OS cells.
Clonal evolution underlying the development of lung metastasis
To track longitudinal and spatial clonal evolution during OS progression, SNVs and arm-level CNAs from the paired primary and metastatic samples were used to infer the evolutionary phylogeny analyzed by Canopy software.
14 Phylogenetic trees give clear overviews of the order of mutation events, allowing the track of emergence and movement of clones from primary to metastatic tumors. The posteriori most likely phylogenetic trees inferred by Canopy using the primary and the metastatic samples from patient P10, P7, and P253 have four clones guided by Bayesian Information Criterion (BIC) and are shown in Fig. 3a-3c , respectively. Numbers of somatic SNVs and arm-level CNAs were shown in the table below the phylogeny. In general, mutations closed to the root of the tree arose earlier than mutations on the tips of the tree.
Clonal evolution analyses revealed that lung metastatic tumors often harbor clones that are nonexistent or rare in matched primary OS tumors. We observed that copy number loss (or loss of heterozygousity) on tumor suppressor genes, including CDKN2A, RB1, and TP53, are generally early events during OS evolution. Interestingly, cell fraction of clones harboring 10q (PTEN) loss are markedly increased in metastatic tumors compared to matched primary tumors (Fig. 3a-3c) . By analyzing the same gene expression dataset (GSE21257) used for KEAP1 analysis, we found that patients with low PTEN expression level show significantly poorer lung metastasis free survival (p 5 0.004, log-rank test; Supporting Information Fig. S5 ). These results strongly suggest that loss of PTEN (or decreased expression) is significantly associated with OS progression and lung metastasis. The phylogenetic trees of other patients (samples with relatively lower tumor purity) were provided in Supporting Information Fig. S6 .
Of note, patient P13 was diagnosed with OS in August 2009 and the primary tumor sample was obtained through surgery in October 2009. Three distinct lung metastatic sites (L1, L2, and L3) were observed and resected at 3, 22, and 44 months, respectively, after the primary tumor sample was obtained (Fig. 3d) . To identify genetic relationships among the primary tumor and three metastases, we first conducted phylogenetic analysis using NJ algorithm. 16 NJ tree based on somatic SNVs (Fig. 3e) or CNAs (Fig. 3f) suggested similar phylogenetic relationships among the primary and three metastatic tumors. Interestingly, two of these metastatic sites (L2 and L3) have more similar SNV profiles and CNA patterns between each other, while the L1 site exhibited a distinctive alteration pattern, which is more closely related to the primary tumor. Sample level phylogenetic analysis suggested that three metastases are polyphyletic origin, opposite to the monoclonal origin commonly seen in metastatic prostate, ovarian and abdominopelvic tumors. [26] [27] [28] The composition of the subclones (Fig. 3g) in the three metastases highly matched the genetic relationships suggested by the NJ tree. L2 and L3 exhibited more similar clone structure. Clone 1 and 5 have relatively high cell fraction in L2 and L3 compared to L1. In contrast, clone 3 and 4 have higher cell fraction in the primary and L1 tumors. Taken together, our results suggest the three metastases were from parallel metastatic events from the primary tumor with a polyphyletic pattern. The earliest metastatic tumor L1 and later metastatic tumors (L2 and L3) are from independent metastatic seeding events.
Discussion
Our analyses of the paired primary and metastatic OS tumor samples indicate that tumors from the same patient are more genetically similar with each other than the tumors from different individuals, consistent with a clonal expansion model and patient specific evolutionary histories. The genomic and evolutionary data presented here begin to establish a framework for tumorigenesis in OS. The ubiquitous presence (in both primary and metastatic tumors) of the amplification of 8q (MYC), loss of chromosome 13 (RB1, BRCA2) or LOH on 17p (TP53) indicates that these are among the early events during OS tumorigenesis. Our data also suggest that loss of 10q (PTEN) are selected for at later stages of tumor progression and lung metastases, a notion supported by an independent clinical association analysis showing patients with lower PTEN expression level have increased probability of lung metastases. Therapeutic targeting of PTEN-PI3K signaling with available inhibitors of PI3K may therefore be warranted for treatment of OS.
Most previous studies observed monoclonal origin of metastatic prostate, pancreatic or endometrial tumors within patient, where all the metastases were more closely related to each other than they were to the primary. [26] [27] [28] Here, we observed longitudinal lung metastases from the primary tumor treated by sequential surgery in patient P13. We found that genetically distinct cell populations in the primary tumor metastasized in parallel to different metastatic tumors. The earliest metastatic tumor L1 and the later metastatic tumors L2 are from independent metastatic seeding events within the primary tumor. The latest metastatic tumor L3 was from sequential spread of metastasis from L2. These results suggest that several distinct cell subpopulations in primary OS tumor may have potentials for metastatic dissemination. In contrast, in a monophyletic model, there are a limited number of cells seeding metastasis. Clinical evidence of rapid OS tumor progression and early metastasis spread to the lung 29 indicates that primary OS tumors have high potential for generating metastases. However, whether polyphyletic seeding is a more common property of OS metastasis will require further studies and validations based on a large number of samples.
Our in vitro experiments exhibited that KEAP1 depletion suppressed the invasion of OS cells. To further examine the role of KEAP1 in metastasis, in vivo experiment using OS metastatic mouse model 30, 31 need to be studied. Numerous experiments indicate that KEAP1 and its target gene NRF2 have dual roles (tumor suppressor or oncogene) in cancer progression. 32 For example, silencing of Nrf2 causes an inhibition of the proliferation of A549 lung cancer cells. 33 In contrast, suppression of Nrf2 by Keap1-directed ubiquitylation enhances cell migration and plasticity in A549 and HepG2 cancer cells. 34 Further, another study found Keap1-deficiency mice displayed increased resistance against the cancer cell metastasis to the lung. 22 Therefore, the oncogenic function of KEAP1 might be essential in the context of metastasis. This is consistent with our association results of KEAP1 from multiple independent cohorts, as higher expression level of KEAP1 is significantly associated with lung metastasis at diagnosis (synchronous metastasis). However, we found that the association between KEAP1 expression and overall survival are not consistent among two studies. 17, 24 In GSE21257 dataset, OS patients with higher KEAP1 expression exhibited a non-significant trend toward poorer overall survival. In contrast, Zhang et al. observed a higher five-year-survival rate for patients with positive Keap1 staining. Several other studies also found no significant difference in overall survival between synchronous and metachronous metastases of different cancer types. 35, 36 One possible explanation is that overall survival results can be impacted by nonsystematic use of subsequent therapy that patients received. Taken together, our results and previous studies suggest that increased expression (or amplification) of KEAP1 is a strong biomarker associated with lung metastasis in OS patients.
